Dr. Romuald Bellmann, Division of General Internal Medicine, Department of Internal Medicine, Innsbruck Medical School, Anichstrasse 35, A-6020 Innsbruck, Austria. E-mail: [email protected]Search for more papers by this author

Helene Vogelsinger,

Helene Vogelsinger

Clinical Pharmacokinetics Unit and

Search for more papers by this author

Michael Joannidis,

Michael Joannidis

Medical Intensive Care Research Unit, Laboratory of Inflammation Research;

Medical Intensive Care Unit and

Search for more papers by this author

Jordan Kountchev,

Jordan Kountchev

Medical Intensive Care Research Unit, Laboratory of Inflammation Research;

Medical Intensive Care Unit and

Search for more papers by this author

Rosa Bellmann-Weiler,

Rosa Bellmann-Weiler

Infectious Diseases Unit, Division of General Internal Medicine, Department of Internal Medicine, Innsbruck Medical School, Innsbruck, Austria

Search for more papers by this author

Christian J. Wiedermann,

Christian J. Wiedermann

Clinical Pharmacokinetics Unit and

Present address: Department of Internal Medicine, General Hospital of Bolzano, Bolzano, Italy.

Search for more papers by this author

Romuald Bellmann,

Corresponding Author

Romuald Bellmann

Clinical Pharmacokinetics Unit and

Medical Intensive Care Unit and

First published: 20 January 2006

https://doi.org/10.1111/j.1525-1594.2006.00192.x

Citations: 9

Share a link

Email
Wechat
Bluesky

Abstract

Abstract: Extracorporeal blood purification techniques such as hemofiltration or albumin dialysis can exert a significant, but not easily predictable influence on plasma pharmacokinetics of antimicrobial agents. The effect of albumin dialysis on the pharmacokinetics of liposomal amphotericin B (AMB) and other lipid-formulated drugs has not been investigated so far. Therefore, plasma concentrations of liberated and liposomal AMB were measured in a patient, who obtained liposomal AMB for suspected invasive mycosis and required albumin dialysis because of cholestatic liver failure caused by graft versus host disease after bone marrow transplantation. Liberated and liposomal AMB were separated by solid phase extraction and measured by high performance liquid chromatography. No excessive AMB elimination took place during albumin dialysis. Plasma levels of liposomal AMB exceeded those of liberated AMB. Pharmacokinetic data were comparable to those obtained previously in patients on hemofiltration and in critically ill patients without extracorporeal blood purification.

REFERENCES

1 Novelli G, Rossi M, Pretagostini R, et al. Use of MARS in the treatment of acute liver failure: preliminary monocentric experience. Transplant Proc 2001; 33: 1942–4.
10.1016/S0041-1345(00)02721-4
CAS PubMed Web of Science® Google Scholar
2 Stange J, Mitzner SR, Klammt S, et al. Liver support by extracorporeal blood purification: a clinical observation. Liver Transplant 2000; 6: 603–13.
10.1053/jlts.2000.7576
CAS PubMed Web of Science® Google Scholar
3 Bellmann R, Graziadei IW, Feistritzer C, et al. Treatment of refractory cholestatic pruritus after liver transplantation with albumin dialysis. Liver Transplant 2004; 10: 107–14.
10.1002/lt.20001
CAS PubMed Web of Science® Google Scholar
4 Bellmann R, Feistritzer C, Zoller H, et al. Treatment of intractable pruritus in drug induced cholestasis with albumin dialysis: a report of two cases. ASAIO J 2004; 50: 387–91.
10.1097/01.MAT.0000132552.58214.00
PubMed Web of Science® Google Scholar
5 Majcher-Peszynska J, Peszynski P, Klammt S, et al. Elimination of antibiotics by albumin dialysis (MARS). Pharmacol Toxicol 2001; 89(Suppl. 1): 88.
Google Scholar
6 Bellmann R, Egger P, Pechlaner C, et al. Levofloxacin elimination during albumin dialysis. Int J Artif Organs 2003; 26: 358–9.
10.1177/039139880302600412
CAS PubMed Web of Science® Google Scholar
7 Adler-Moore JP, Proffitt RT. Development, characterization, efficacy and mode of action of AmBisome, a unilamellar liposomal formulation of amphotericin B. J Liposome Res 1993; 3: 429–50.
10.3109/08982109309150729
CAS Google Scholar
8 Boswell GW, Buell D, Bekersky I. AmBisome (liposomal amphotericin B): a comparative review. J Clin Pharmacol 1998; 38: 583–92.
10.1002/j.1552-4604.1998.tb04464.x
CAS PubMed Web of Science® Google Scholar
9 Egger P, Bellmann R, Wiedermann CJ. Determination of amphotericin B, liposomal amphotericin B, and amphotericin B colloidal dispersion in plasma by high-performance liquid chromatography. J Chromatogr B Biomed Sci Appl 2001; 760: 307–13.
10.1016/S0378-4347(01)00292-4
CAS PubMed Web of Science® Google Scholar
10 Bellmann R, Egger P, Gritsch W, et al. Amphotericin B lipid formulations in critically ill patients on continuous veno-venous haemofiltration. J Antimicrob Chemother 2003; 51: 671–81.
10.1093/jac/dkg139
CAS PubMed Web of Science® Google Scholar
11 Bekersky I, Fielding RM, Dressler DE, Lee JW, Buell DN, Walsh TJ. Plasma protein binding of amphotericin B and pharmacokinetics of bound versus unbound amphotericin B after administration of intravenous liposomal amphotericin B (AmBisome) and amphotericin B deoxycholate. Antimicrob Agents Chemother 2002; 46: 834–40.
10.1128/AAC.46.3.834-840.2002
CAS PubMed Web of Science® Google Scholar
12 Bellmann R, Egger P, Wiedermann CJ. Differences in pharmacokinetics of amphotericin B lipid formulations despite clinical equivalence. Clin Infect Dis 2003; 36: 1500–1.
10.1086/374876
CAS PubMed Web of Science® Google Scholar

Citing Literature

Volume30, Issue2

February 2006

Pages 118-121

Pharmacokinetics of Liposomal Amphotericin B During Extracorporeal Albumin Dialysis

Abstract

REFERENCES

Citing Literature

References

Information

About Wiley Online Library

Help & Support

Opportunities

Connect with Wiley

Pharmacokinetics of Liposomal Amphotericin B During Extracorporeal Albumin Dialysis

Abstract

REFERENCES

Citing Literature

References

Related

Information